2019年GUPS前列腺癌分级白皮书
2019年泌尿生殖病理学会(GUPS)发布白皮书,通过文献综述和病理/临床调查更新前列腺癌分级建议,涵盖%GP4报告、 tertiary pattern、MRI靶向活检评分、GrGp术语、筛状癌和导管内癌报告、分子检测及人工智能应用等。
要点
- 报告%GP4:穿刺活检GrGp2/3及部分GS4+4=8病例报告,分<5%、<10%和10%递增。
- 根治标本GrGp2/3且GP5<5%时使用minor TP5,GS和GrGp基于原GS。
- 报告筛状癌和IDC-P,IDC-P不纳入最终GS/GrGp,必要时用基底细胞免疫染色。
核心结论
- 更新前列腺癌分级推荐,涵盖%GP4、三级模式、MRI靶向活检、GrGp、筛状癌、IDC-P、分子检测和人工智能等。
研究设计与样本
- 基于文献批判性综述以及病理学家和临床医生调查的共识声明。
主要发现
- 穿刺活检GrGp2和3应报告%GP4,GrGp2和3且<5% GP5时报告minor TP5。
- 多针MRI靶向 lesion 作为一个整体评分,全局评分整合系统和靶向结果。
- 筛状癌和IDC-P在活检和根治标本中报告,IDC-P不纳入最终GS/GrGp。
关键数值与推荐
- 报告%GP4分<5%或<10%及之后10%递增;minor TP5仅用于RP GrGp2/3且GP5<5%。
- IDC-P诊断标准:密集筛状腺体(>50%上皮)、实性巢和/或显著异型性/坏死。
- 保留GS 3+5=8在GrGp4;Ki67不常规临床使用,PTEN和RNA检测需进一步研究。
临床怎么用
- 按推荐报告%GP4、minor TP5、筛状癌和IDC-P,使用GrGp术语。
- MRI靶向活检多针未指定时给整体评分,提供全局评分时整合系统和靶向结果。
- IDC-P不纳入最终GS/GrGp,必要时用基底细胞免疫染色鉴别。
局限性
- 基于文献综述和调查的共识,部分建议证据级别未明确。
- 分子检测和人工智能应用尚未成熟,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Controversies and uncertainty persist in prostate cancer grading. OBJECTIVE.—: To update grading recommendations. DATA SOURCES.—: Critical review of the literature along with pathology and clinician surveys. CONCLUSIONS.—: Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace "tertiary grade pattern" in radical prostatectomy (RP) with "minor tertiary pattern 5 (TP5)," and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)-targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDC-P) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) "atypical intraductal proliferation (AIP)" is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.
引用
- Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med. 2021. PMID: 32589068. doi:10.5858/arpa.2020-0015-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。